RBC upgrades Sartorius on stronger outlook, AI opportunities

By Reuters News

** RBC upgrades German pharmaceutical equipment supplier Sartorius SATG.DE to "outperform" from "sector perform", citing an improving outlook, accelerating growth prospects and potential benefits from AI-driven demand

** The broker points to the company's raised guidance, supported by favourable foreign exchange trends as well as expectations for faster underlying growth in 2027

** AI is emerging as a demand driver across biopharma and academia, with Sartorius set to benefit through its LPS division and small-scale bioreactor range, RBC says

** Out of four analysts covering the stock, one rates it "strong buy", two "buy" and one "hold" - LSEG data



($1 = 0.8919 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.